In this Q&A, Mineralys CEO Jon Congleton discusses how targeting aldosterone could reshape hypertension treatment. Aldosterone synthase inhibitors (ASIs) are drawing a lot of attention. What first ...
A study has determined that adverse effects leading to treatment discontinuation vary among different blood pressure-lowering drug classes.
The retrospective study found patients on Bruton’s tyrosine kinase inhibitors are similar to the general population in the sense that it usually takes at least 2 anti-hypertensive drugs to control ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results